JB Pharma reports revenue growth of 14% in Q3 FY25; Net profit up by 22%
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
The company will showcase groundbreaking innovations from its Pharma and Nutrition divisions, highlighting key ingredients and formulations designed to support holistic well-being
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business
Torrent Pharmaceuticals has reported total income of Rs. 2,842 crores during the period ended December 31, 2024
The camp, operational daily from 12 PM to 4 PM, offers free health check-ups, blood pressure monitoring
The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization
Q3 FY25 revenue up 24% to Rs 3,230 crore
PAT after MI is Rs. 41 crore which is 162% increase
Subscribe To Our Newsletter & Stay Updated